BRIEF published on 12/11/2025 at 23:05, 3 days 11 hours ago Xenetic Biosciences ajourne son assemblée générale annuelle des actionnaires de 2025. Instructions De Vote Quorum Biosciences Xénétiques Assemblée Générale Des Actionnaires Ajournement De 2025
BRIEF published on 12/11/2025 at 23:05, 3 days 11 hours ago Xenetic Biosciences Adjourns 2025 Annual Stockholders Meeting Xenetic Biosciences Stockholders Meeting Voting Instructions Quorum 2025 Adjournment
PRESS RELEASE published on 12/11/2025 at 23:00, 3 days 11 hours ago Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting Xenetic Biosciences, Inc. adjourns 2025 Annual Meeting of Stockholders due to lack of quorum. Stockholders urged to vote before reconvened meeting on January 8, 2026 Xenetic Biosciences Stockholders Quorum Proxy Vote 2025 Annual Meeting
BRIEF published on 11/19/2025 at 14:50, 25 days 19 hours ago Xenetic Biosciences étend sa collaboration avec Scripps Research Biopharmaceutique Traitement Du Cancer DNase I Thérapie CAR-T Recherche Scripps
BRIEF published on 11/19/2025 at 14:50, 25 days 19 hours ago Xenetic Biosciences Extends Collaboration with Scripps Research Cancer Treatment Biopharmaceutical DNase I CAR-T Therapy Scripps Research
PRESS RELEASE published on 11/19/2025 at 14:45, 25 days 19 hours ago Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform Xenetic Biosciences extends collaboration with Scripps Research to advance DNase-based immuno-oncology treatment for cancers Xenetic Biosciences Immuno-oncology DNase I CAR-T Therapy Scripps Research
BRIEF published on 11/13/2025 at 14:50, 1 month 1 day ago Xenetic Biosciences publie ses résultats financiers du troisième trimestre 2025 Résultats Financiers Essais Cliniques Augmentation Des Revenus Technologie DNase Carcinome Pancréatique
BRIEF published on 11/13/2025 at 14:50, 1 month 1 day ago Xenetic Biosciences Reports Q3 2025 Financial Results Financial Results Revenue Increase Clinical Trials Pancreatic Carcinoma DNase Technology
PRESS RELEASE published on 11/13/2025 at 14:45, 1 month 1 day ago Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q3 2025 financial results, focuses on DNase-based technology for cancer treatment. Secured $3.9 million from offering, advancing collaborations Xenetic Biosciences Cancer Treatment Collaborations DNase Technology Q3 2025 Financial Results
BRIEF published on 10/10/2025 at 15:35, 2 months 4 days ago Xenetic Biosciences Announces $4.5 Million Stock Offering Xenetic Biosciences Biopharmaceutical Immuno-oncology Stock Offering Canaccord Genuity
Published on 12/15/2025 at 09:01, 1 hour 43 minutes ago Apex Discovers Mineralized Carbonatite at its Lac Le Moyne Project, Québec
Published on 12/14/2025 at 23:00, 11 hours 44 minutes ago Fortescue to Acquire Alta Copper for C$1.40 per Share
Published on 12/13/2025 at 02:00, 2 days 8 hours ago Battery X Metals Announces Confidential Submission of Draft Registration Statement with the U.S. Securities and Exchange Commission in Connection with Proposed U.S. National Securities Exchange Initial Public Offering
Published on 12/13/2025 at 00:13, 2 days 10 hours ago Prospect Ridge Announces Non-Brokered Private Placement
Published on 12/12/2025 at 23:05, 2 days 11 hours ago ReelTime's RLTR Stock Surges Past AI Giants Following LG Smart TV Debut of Reel Intelligence
Published on 12/15/2025 at 10:30, 14 minutes ago EQS-Adhoc: Gothaer Allgemeine Versicherung AG: BarmeniaGothaer closes its first financial year 2025 with a very good result
Published on 12/15/2025 at 10:15, 29 minutes ago Now Is Yours: Huawei Rolls Out Mate X7 Alongside a New Lineup of Innovative Products
Published on 12/15/2025 at 10:09, 35 minutes ago FAVEOS SE concludes strategic framework agreements with leading battery optimizers enspired and Entrix
Published on 12/15/2025 at 10:05, 39 minutes ago Voltage Energy Secures Industry's First Full-System 2kV EBOS Certification from UL Solutions
Published on 12/12/2025 at 18:00, 2 days 16 hours ago Disclosure of trading in own shares between November 24th and November 28th, 2025
Published on 12/12/2025 at 18:00, 2 days 16 hours ago Déclaration des transactions sur actions propres réalisées du 24 novembre au 28 novembre 2025
